AbbVie is conducting a study titled ‘SUNRISE-UC’ to evaluate the effectiveness and safety of Risankizumab in patients with moderate to severe ulcerative colitis. This real-world study aims to assess ...

The interventions being tested include risankizumab, ABBV-382, and lutikizumab. These drugs are administered either as subcutaneous injections or intravenous infusions, with the goal of reducing ...